Loading…
Loading…
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27, 2026.
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026.
NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") is pleased to announce that it has entered into a mineral property purchase agreement dated November 28, 2025 (the "Purchase Agreement") with Storm Exploration Inc., a company listed on the TSX Venture Exchange, ("Storm") whereby the Company has agreed to acquire a number of mineral claims, patented claims and mining licence located in the Miminiska-Fort Hope greenstone belt in the Thunder Bay North Mining District, Ontario (the "Miminiska Gold Property" or the "Property"). To reflect this new direction, the Company also announces it will be changing its name to "Canadian Goldfields Discovery Corp." and will advise on timing of the name and symbol change prior to it occurring.
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / Storm Exploration Inc. (TSXV:STRM) ("Storm" or the "Company") is pleased to announce that it has entered into a mineral property purchase agreement (the "Definitive Agreement") dated November 28, 2025 with European Electric Metals Inc. (TSXV: EVX) ("European Electric"), pursuant to which Storm will sell, subject to the satisfaction of certain conditions, its interest in the Miminiska Project, located in northwestern Ontario, that Storm will acquire by exercising its option to acquire the Mininiska Project pursuant to an existing option agreement dated May 5, 2021, as amended (the "Option Agreement") between Storm and Landore Resources Canada Inc. ("Landore") (collectively, the "Transaction"). The Transaction is an arm's length transaction.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for EVX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.